SEC Form 8-K filed by Crinetics Pharmaceuticals Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 13, 2024, Crinetics Pharmaceuticals, Inc. (the “Company”) determined that James Hassard will separate from the Company and will cease serving as the Chief Commercial Officer, effective October 14, 2024.
Pursuant to the Employment Agreement, dated February 16, 2022, between the Company and Mr. Hassard (the “Employment Agreement”), which is filed as Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and is incorporated herein by reference, subject to Mr. Hassard’s execution of a release of claims in favor of the Company, its affiliates and their respective officers and directors, Mr. Hassard will be entitled to receive the payments and benefits associated with a termination without cause, as set forth in the Employment Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Crinetics Pharmaceuticals, Inc. |
|
|
|
|
Date: |
September 17, 2024 |
By: |
/s/ R. Scott Struthers, Ph.D. |
|
|
|
R. Scott Struthers, Ph.D. |